Are these combos suitable for people with celiac disease or gluten sensitivities
Am J Clin Dermatol 9:1531 Donath MY, Shoelson SE (2011) Type 2 diabetes as an inflammatory disease
SGLT2 inhibitors, such as empagliflozin and canagliflozin, have similar A1C-lowering properties (0.5%-0.8%) and out-of-pocket costs (except for alogliptin, which is available generically), but have the added advantages of CV risk reduction, BP-lowering, and weight loss
Products can differ in size, shape, color, and markings from country to country
However, this relationship does not account for the differences in HR increases within the sub-class of the long-acting agents